Nachahmerpräparate

Nachahmerpräparate, commonly known as generics, are pharmaceutical products that are therapeutically equivalent to brand-name drugs but are generally sold at a lower cost. They contain the same active ingredients, dosage form, strength, and route of administration as their originator counterparts. The development and approval of generics are regulated by national health authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These regulatory bodies require generic manufacturers to demonstrate bioequivalence, meaning that the drug is absorbed into the bloodstream at the same rate and extent as the brand-name drug. This ensures that the generic product will produce the same therapeutic effect.

The patent protection for a brand-name drug eventually expires, allowing other companies to produce and market generic versions. This competition significantly drives down the price of medications, making healthcare more affordable for patients and reducing overall healthcare expenditure. While the active ingredient is identical, generics may differ in their inactive ingredients, such as fillers, binders, or colorants. These differences are generally not clinically significant, but in rare cases, individuals may experience sensitivities. Choosing between a brand-name drug and a generic is often a matter of cost, as both are considered safe and effective alternatives.